[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Elaine Chow\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100567680","chronic-dorzagliatin-on-insulin-and-incretin-function-in-intermediate-hyperglycemia-and-type-2-diabetes-100567680",false,"NCT06671340","Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes","Effects of Repeated Dose of Dorzagliatin on Insulin Secretion, Glucagon Release and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes","Inclusion Criteria:\n\n1. Individuals aged ≥ 18 years but \\\u003C 70 years\n2. Male or female\n3. Body mass index of over 18 kg\u002Fm2 and \\\u003C 35 kg\u002Fm2\n\nAdditional inclusion criteria for IH group\n\n* Fasting plasma glucose \\\u003C7.0 mmol\u002FL and HbA1c \\\u003C 6.5%\n* 1 hour plasma glucose ≥8.6 and \\\u003C11.6 mmol\u002FL on 75g oral glucose tolerance test (OGTT)\n* No use of glucose lowering drugs in past 6 months\n\nAdditional inclusion criteria for T2D group\n\n* HbA1c 6.5 to 10% at screening\n* On diet control, or stable dose of oral glucose lowering drugs metformin for at least 8 weeks\n\nExclusion Criteria:\n\n* 1\\. Subjects who do not agree to participate in this study. 2. Country of birth is unknown. 3. Body weight less than 45kg. 4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).\n\n  5\\. Subjects with severe renal dysfunction as defined by eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 or patients receiving renal dialysis (such as haemodialysis or continuous ambulatory peritoneal dialysis).\n\n  6\\. Severe hepatic dysfunction as defined by aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) \\> 3 times upper limit of normal.\n\n  7\\. Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or history of myocardial infarction within last 12 months.\n\n  8\\. History of drug abuse or excessive alcohol intake based on investigator judgment.\n\n  9\\. Dehydration, diarrhoea or vomiting at the time of recruitment. 10. Subjects with severe infection, in perioperative period or with serious injury at the time of recruitment.\n\n  11\\. Subjects with anaemia (Haemoglobin \\\u003C9.0mg\u002FdL). 12. Pregnant or lactating or intending to become pregnant within 30 days after last dose of study drug.\n\n  13\\. Participation in a clinical trial with investigational product within 30 days before enrolment.\n\n  14\\. Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥300 mL of blood within 30 days prior to study drug administration.\n\n  15\\. Subjects judged unsuitable for the study based on investigator judgment. 16. Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued.\n\n  17\\. Unwilling or unable to follow protocol requirements.","ALL","18 Years","70 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","A total of 30 subjects will be recruited 15 with intermediate hyperglycemia and 15 in the tyep 2 diabetes group respectively. Eligible participants will undergo hyperglycemic-clamp\u002Foral glucose tolerance at baseline and after 4 weeks of dorzagliatin treatment.",[27,28],"Diabetes Mellitus","Prediabetes \u002F Type 2 Diabetes",[30,31,32],"clamp","diabetes","glucokinase activator","NOT_YET_RECRUITING","2025-03-01",{"date":36,"type":37},"2025-03-04","ACTUAL",{"date":39,"type":21},"2025-04-02",{"date":41,"type":21},"2026-01-31",{"name":43,"class":44},"Elaine Chow","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100580555","cgm-in-icodextrin-pd-100580555","NCT06838819","CGM in Icodextrin PD","Evaluation of Accuracy of Medtronic Simplera™ CGM in Patients on Icodextrin-containing Peritoneal Dialysis Regimens","Inclusion Criteria:\n\n1. Type 1 or 2 diabetes mellitus for at least 3 months\n2. On continuous ambulatory peritoneal dialysis (CAPD) or APD for at least 2 months\n3. On icodextrin PD solutions for at least 1 month or planned for switching to icodextrin PD solutions within 3 months of screening\n4. Male or female age ≥ 18 years old and ≤ 75 year old.\n5. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.\n6. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.\n7. Willingness to abstain from swimming during their participation in the measurement phase.\n8. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.\n9. Written informed consent to participate in the study provided by the patient.\n\nExclusion Criteria:\n\n1. Poorly controlled diabetes mellitus with HbA1c\\>11%\n2. Peritonitis within 1 month of screening\n3. Planned for switching to hemodialysis or living donor transplant in the future 1 month\n4. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential\n5. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.\n6. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.\n7. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.\n8. Extensive skin changes\u002Fdiseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).\n9. Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study.\n10. Blood donation of more than 500 ml within the last three months\n11. Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.\n12. Has a MRI scan, CT scan, or diathermy scheduled during the proposed study participation.\n13. An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).\n14. Women of reproductive potential who are unwilling to adopt contraceptive measures during the study period\n15. Patients with history of pacemaker and prosthesis implantation.\n16. Continuous use of real-time CGM for personal diabetes management in the three months prior to screening (sensor use \\>80% of time)","75 Years",{"count":20,"type":21},"OBSERVATIONAL","Assessment of performance (precision and accuracy) of Simplera™ CGM as compared with a gold standard reference laboratory method (YSI glucose) in diabetes patients on peritoneal dialysis with icodextrin",[58,59,60,61],"Diabetes Mellitus (Diagnosis)","End Stage Renal Disease (ESRD)","Dialysis","Continuous Glucose Monitoring","2025-02-17",{"date":64,"type":37},"2025-02-21",{"date":66,"type":21},"2025-02-20",{"date":68,"type":21},"2026-09-20",{"name":43,"class":44},""]